Chyawanprash Brand Positioning Through Traditional Wellness and Modern Health: The Dabur Chyawanprash Case

Industry and Competitive Context

Chyawanprash is a herbal Ayurvedic formulation sold in India as an immunity and general-health product. Dabur describes itself as the largest Ayurvedic company in India and worldwide, and its FY2025 annual report places Dabur Chyawanprash among three brands with revenue above ₹500 crore, alongside Dabur Honey and Odonil. The report also shows Health Supplements, the category that houses Chyawanprash, at 15% of the India FMCG business revenue mix.

The most citable estimate is from 2021, when Business Today reported industry estimates of a ₹700–800 crore market in which Dabur held at least 50%. CRISIL’s November 2023 rating rationale put Dabur’s share in the Chyawanprash-led health supplements segment at about 63%, and Dabur’s own FY2025 report states 65.8%. The source passage does not say whether the 65.8% is by value or volume.

Competition has come from two directions. Established Ayurveda players such as Zandu and Patanjali already operate in the category, and in 2021 Marico entered through its Saffola brand within the Immuniveda range. In that coverage, an independent industry advisor noted that Saffola lacked an Ayurvedic lineage and that many local practitioners market their own formulations. That is one commentator’s view, not a measured finding.

The second direction is advertising conflict. In July 2025 the Delhi High Court issued an interim order on a suit by Dabur, directing Patanjali to modify advertisements for Patanjali Special Chyawanprash that Dabur alleged disparaged its product. Dabur’s plea, as reported, said the advertisement misrepresented Patanjali’s own formulation, cast doubt on Dabur’s Ayurvedic authenticity and portrayed Dabur’s product as inferior. On 23 September 2025 a division bench disposed of Patanjali’s appeal: it allowed the line asking why consumers should settle for ordinary Chyawanprash, but required removal of the reference to being made with 40 herbs. A later report says the court also restrained a separate Patanjali advertisement that called other brands’ Chyawanprash “dhoka” (deception).

Analytical reading. The category is concentrated, with one brand holding roughly two-thirds of the market on the company’s account. Rivals therefore compete less on distribution alone and more on who may credibly claim Ayurvedic authenticity. The litigation shows that “authenticity” and the “40 herbs” formulation claim are contested assets, and the courts have drawn a line between permissible puffery and impermissible comparison.

Brand Situation Prior to the Campaign Programme

The documented baseline starts with the pandemic. In May 2020, Dabur’s CEO said the company was seeing a 400% surge in demand for Dabur Chyawanprash, that stock-outs were occurring, and that the company had invested in expanding capacity. The same coverage reported that Dabur gained share in Chyawanprash during FY2020. A May 2021 results presentation cited a Chyawanprash share gain of about 170 bps. A third-party summary of the FY2022 annual report states that share improved by about 2.5% and that the sugar-free variant grew at double digits. Dabur’s FY2023 annual report page reports a 20 bps share increase and 26 million units sold in a year.

By FY2025 the company reported that, despite weaker winters hurting offtake, the brand reached its highest-ever share of 65.8%, up 140 bps, and that this was ahead of its share during the COVID period. The weak winter matters because it exposes a seasonal dependency that the company itself acknowledged.

Analytical reading. The pandemic produced an unusual spike in immunity-led demand. The documented question afterwards was whether share and relevance could be held once the emergency framing faded and winter was the main consumption season. The FY2025 statement that share exceeded its pandemic-period level is the company’s evidence that the gains were retained.

Strategic Objective

The documented objectives are qualitative and stated per initiative. The FY2025 report says a special monsoon campaign aimed to build the brand’s year-round relevance as an immunity booster, by highlighting the greater risk of illness from airborne viruses and germs during the monsoon. A sugar-free variant campaign aimed to raise awareness of immunity and of maintaining healthy blood sugar, ahead of World Diabetes Day. A women-focused variant, Dabur Khajurprash, was launched to raise awareness of iron deficiency, haemoglobin and immunity. A winter initiative aimed at children’s immunity awareness is described below.

At the corporate level, Dabur states that driving household penetration is a major factor in securing future growth.

Analytical reading. The stated aims extend where and when the product is relevant: across seasons, to people managing blood sugar, to women, and to children. None of the documented aims is to win share from a named competitor, even though share gains are reported as outcomes.

Campaign Architecture and Execution

FY2025 (April 2024 to March 2025). Dabur’s annual report lists five initiatives for the brand. First, a monsoon campaign used headgear as a creative device to show that prevention can be the best cure. Second, for Durga Puja the brand worked with former India cricket captain Sourav Ganguly on an AI-led campaign called “Pujo with Dada”, which let consumers send personalised AI video wishes through a dedicated website. Third, the sugar-free variant ran a television commercial titled “Aapka Angrakshak” as a run-up to World Diabetes Day. Fourth, the Khajurprash variant, made primarily from dates with 40+ Ayurvedic herbs, was launched with shooter and double Olympic medallist Manu Bhaker as brand ambassador and an integrated media campaign. Fifth, with the onset of winter, the “Immune India” campaign engaged doctors to run immunity awareness sessions for underprivileged children.

FY2026 (April 2025 to March 2026). Dabur’s Q2 FY2026 investor presentation features a campaign titled “Daily Two Spoons for Monsoon”. The Q3 and Q4 FY2026 presentations feature “Taiyaar ya Beemaar?”, and the Q3 deck also lists an influencer and digital initiative, “Health ki SIP”. The reviewed sources give titles only, with no description of creative content, flighting or duration.

Analytical reading. The documented programme has four layers. The first is a seasonal layer (monsoon and winter). The second is a segment layer (blood-sugar-conscious consumers, women, children). The third is a cultural-occasion layer (Durga Puja). The fourth is a product-line layer (sugar-free, Khajurprash and, in FY2026, premium variants). Each layer is a separate reason to use the product, which is consistent with the stated goal of year-round relevance.

Positioning and Consumer Insight

The positioning language in the sources combines two vocabularies. The traditional vocabulary is Ayurveda: the company’s self-description as the largest Ayurvedic company, the 40+ herb formulation, and, in the competitive dispute, the question of who is authentically Ayurvedic. The modern vocabulary is health management: immunity, blood-sugar awareness, iron deficiency and haemoglobin. It is delivered through AI-generated personalised video, an influencer campaign and doctor-led sessions.

The only consumer insight Dabur states publicly is the monsoon one: infection risk from airborne viruses and germs rises in that season, so prevention matters. In Q3 FY2026, Dabur also reported strong growth in premium variants, Gur Chyawanprash and Ratnaprash. The reviewed sources do not describe the positioning of these variants beyond their names.

Analytical reading. Tradition appears to supply the credential and modern health language supplies the occasion. A consumer who accepts the Ayurvedic credential is given reasons to buy outside the winter default: a monsoon reason, a diabetes-aware reason, a women’s nutrition reason, a children’s reason. This is an interpretation of documented executions and not a company-stated positioning framework. The Delhi High Court dispute suggests the credential itself is where rivals attack.

Media and Channel Strategy

The verified media elements are television commercials (sugar-free “Aapka Angrakshak”), an integrated media campaign with a sports ambassador (Khajurprash), AI-enabled digital engagement (“Pujo with Dada”), influencer and digital content (“Health ki SIP”), and on-ground doctor-led awareness sessions (“Immune India”). In Q2 FY2026, Dabur linked its 234 bps Chyawanprash share gain to focused media initiatives. That is the company’s attribution and was not independently tested.

Distribution facts are company-wide, not brand-specific. In FY2025 Dabur reported reach of 8.4 million retail outlets, up from 7.9 million, and rural coverage of 1.32 lakh villages. It described e-commerce as its fastest-growing channel, with quick commerce as the primary growth engine within it. Advertisement and publicity expense was ₹864.6 crore in FY2025 (6.9% of revenue from operations) against ₹849.1 crore (6.8%) in FY2024.

Business and Brand Outcomes

FY2025. Dabur reported a highest-ever market share of 65.8%, up 140 bps, despite weaker winters. Company-wide, revenue from operations was ₹12,563 crore, up 1.3%.

Q1 FY2026. Dabur reported strong double-digit Chyawanprash growth attributed to the early onset of the monsoon, and a share gain of 111 bps.

Q2 FY2026. Dabur reported that Chyawanprash maintained leadership with a 234 bps share gain, which it linked to focused media initiatives. Health Supplements category value growth was mid-single digit.

Q3 FY2026. Chyawanprash secondary sales showed positive growth while primary sales were flattish, and premium variants Gur Chyawanprash and Ratnaprash grew strongly.

Q4 and full-year FY2026. The Q4 presentation reviewed shows the “Taiyaar ya Beemaar?” campaign.

Limits of the evidence. The outcomes are company-reported. They show correlation between campaign periods and share movements, and they do not isolate the effect of advertising from weather, pricing, distribution or competitor activity. The company itself credits the early monsoon for Q1 FY2026 growth and the weak winter for FY2025 offtake, and these are weather effects the campaigns did not cause.

Strategic Implications

Growth at high share depends on occasions. With the company reporting about two-thirds of the category, further growth cannot rely only on taking share from competitors. The documented actions point to widening when and why the product is used: a monsoon programme, a sugar-free variant, a women-focused variant and premium lines. Weather evidence is consistent with this. Weaker winters pressured FY2025 offtake, and an early monsoon supported Q1 FY2026 growth. A brand tied to one season carries weather risk, and year-round positioning is the documented response.

Tradition is a defended asset. Dabur’s heritage claims are part of its value, and the 2025 litigation shows leaders and challengers fighting over the language of authenticity. The court’s split outcome, allowing “ordinary” as puffery while removing the “40 herbs” comparison, shows how little room comparative claims have in an Ayurvedic category. For a leader, the choice between suing a rival and ignoring it is itself a strategic decision with costs on both sides, but the sources contain no information on how Dabur weighed it.

Modernisation extends the brand and may strain it. AI video, influencer content and premium variants widen the audience. The reviewed sources do not show whether these moves affect the brand’s traditional credential, either positively or negatively, and Q3 FY2026 primary sales were described as flattish. This case therefore stops short of calling the modernisation strategy a success.

The evidence base is narrow. Everything verifiable is company-reported or press-reported. Anyone applying this case should recognise that consumer research, spend and campaign-level returns are not public.

Discussion Questions

1. Dabur reports roughly two-thirds category share. Using only the documented initiatives, evaluate whether further growth is more likely to come from new usage occasions, new segments or new competitor share. What evidence would you need to decide, and which of it is not public?

   
   

2. The monsoon, sugar-free, women’s and children’s initiatives each address a different reason to consume. Assess the risks of building a brand through many parallel positioning claims, and explain how a leader should decide which to prioritise.

   
   

3. The Delhi High Court allowed a rival to call competing products “ordinary” but not to cite the “40 herbs” formulation. What does this imply for how an incumbent should build and defend a heritage-based claim, and for how a challenger should position against it?

   
   

4. Dabur linked a 234 bps Q2 FY2026 share gain to focused media initiatives, while attributing other swings to weather. How would you design a measurement approach to separate advertising effects from seasonality, and what data would you require?

   
   

5. The case combines Ayurvedic tradition with AI-based, influencer-led and premium extensions. Argue for and against the view that modernisation strengthens a traditional-wellness brand, and state which documented evidence supports each side.